IL105329A - תכשיר רוקחות לטיפול בגידולים ממאירים באמצעות תולדות (2- הלומתילידן ותכשיר אנטיניאופלסטי הספציפי לפאזה s או פאזה m - Google Patents

תכשיר רוקחות לטיפול בגידולים ממאירים באמצעות תולדות (2- הלומתילידן ותכשיר אנטיניאופלסטי הספציפי לפאזה s או פאזה m

Info

Publication number
IL105329A
IL105329A IL105329A IL10532993A IL105329A IL 105329 A IL105329 A IL 105329A IL 105329 A IL105329 A IL 105329A IL 10532993 A IL10532993 A IL 10532993A IL 105329 A IL105329 A IL 105329A
Authority
IL
Israel
Prior art keywords
group
halogen
hydrogen
formula
phase
Prior art date
Application number
IL105329A
Other languages
English (en)
Other versions
IL105329A0 (en
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of IL105329A0 publication Critical patent/IL105329A0/xx
Publication of IL105329A publication Critical patent/IL105329A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL105329A 1992-04-10 1993-04-07 תכשיר רוקחות לטיפול בגידולים ממאירים באמצעות תולדות (2- הלומתילידן ותכשיר אנטיניאופלסטי הספציפי לפאזה s או פאזה m IL105329A (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86639992A 1992-04-10 1992-04-10

Publications (2)

Publication Number Publication Date
IL105329A0 IL105329A0 (en) 1993-08-18
IL105329A true IL105329A (he) 1998-06-15

Family

ID=25347526

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105329A IL105329A (he) 1992-04-10 1993-04-07 תכשיר רוקחות לטיפול בגידולים ממאירים באמצעות תולדות (2- הלומתילידן ותכשיר אנטיניאופלסטי הספציפי לפאזה s או פאזה m

Country Status (17)

Country Link
US (2) US20040102461A1 (he)
EP (1) EP0664708B1 (he)
JP (1) JP3713668B2 (he)
KR (1) KR100258668B1 (he)
AT (1) ATE170077T1 (he)
AU (1) AU667527B2 (he)
CA (1) CA2117891C (he)
DE (1) DE69320646T2 (he)
DK (1) DK0664708T3 (he)
ES (1) ES2123642T3 (he)
HU (1) HU219476B (he)
IL (1) IL105329A (he)
MX (1) MX9302038A (he)
NZ (1) NZ251211A (he)
TW (1) TW362971B (he)
WO (1) WO1993020825A1 (he)
ZA (1) ZA932455B (he)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2768295A (en) * 1994-07-11 1996-02-09 Hoechst Marion Roussel, Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
US5811408A (en) * 1994-07-12 1998-09-22 Yamasa Corporation 2'-deoxy-2'-(substituted or unsubstituted)methylidene-4'-thionucleosides
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
CA2302754C (en) 1997-09-04 2011-11-08 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
US6544962B1 (en) 2000-11-02 2003-04-08 Matrix Pharmaceutical, Inc. Methods for treating cellular proliferative disorders
BR0307712A (pt) * 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
WO2004042081A1 (de) * 2002-11-04 2004-05-21 Charité-Universitätsme Dizin Berlin Spezifische haplotypen des mdr1-gens und deren anwendung in der diagnose und therapie
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CA2806232A1 (en) 2010-07-23 2012-01-26 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
JP2015500833A (ja) 2011-12-09 2015-01-08 デメレックス， インコーポレイテッド ノルイボガインのリン酸エステル
EP2794627B1 (en) 2011-12-22 2018-09-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
EP2934541A4 (en) 2012-12-20 2016-08-03 Demerx Inc NORIBOGAINE SUBSTITUTE
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them

Also Published As

Publication number Publication date
KR950700749A (ko) 1995-02-20
JPH07505653A (ja) 1995-06-22
ZA932455B (en) 1993-10-20
JP3713668B2 (ja) 2005-11-09
US20050032738A1 (en) 2005-02-10
KR100258668B1 (ko) 2000-07-01
EP0664708A1 (en) 1995-08-02
HUT71224A (en) 1995-11-28
AU667527B2 (en) 1996-03-28
MX9302038A (es) 1993-10-01
TW362971B (en) 1999-07-01
IL105329A0 (en) 1993-08-18
CA2117891A1 (en) 1993-10-28
CA2117891C (en) 1998-07-07
EP0664708B1 (en) 1998-08-26
HU219476B (hu) 2001-04-28
AU3813193A (en) 1993-11-18
EP0664708A4 (en) 1995-04-24
US20040102461A1 (en) 2004-05-27
HU9402914D0 (en) 1995-01-30
WO1993020825A1 (en) 1993-10-28
DE69320646D1 (de) 1998-10-01
NZ251211A (en) 1997-05-26
DE69320646T2 (de) 1999-01-14
ES2123642T3 (es) 1999-01-16
DK0664708T3 (da) 1998-11-02
ATE170077T1 (de) 1998-09-15

Similar Documents

Publication Publication Date Title
EP0664708B1 (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
US5561136A (en) Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
JP5730854B2 (ja) デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用
WO2016014778A1 (en) Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
JP2012522842A (ja) シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
EP4004002A1 (en) Macrocyclic compounds as sting agonists and methods and uses thereof
US8383605B2 (en) Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
EP3068406B1 (en) Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment
US9844529B2 (en) Combination therapy for ovarian cancer
JP5687687B2 (ja) 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
EP0490380B1 (en) Use of N,N'-bis 3-(ethylamino)propyl -1,7-heptanediamine and a cytotoxic agent
AU2008356312A1 (en) Antitumor agent, kit, and method for treating cancer
JP5581200B2 (ja) シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤
US20060258736A1 (en) Dosing regimen
NZ623622B2 (en) Combination therapy for ovarian cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees